Oakworth Capital, Inc. Sorrento Therapeutics, Inc. Transaction History
Oakworth Capital, Inc.
- $1.68 Billion
- Q3 2025
A detailed history of Oakworth Capital, Inc. transactions in Sorrento Therapeutics, Inc. stock. As of the latest transaction made, Oakworth Capital, Inc. holds 350 shares of SRNE stock, worth $115. This represents 0.0% of its overall portfolio holdings.
Number of Shares
350Holding current value
$115% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SRNE
# of Institutions
13Shares Held
5.37MCall Options Held
0Put Options Held
0-
B. Riley Securities, Inc. Los Angeles, CA5.22MShares$1.72 Million1.01% of portfolio
-
Swisspartners Ltd. Vaduz, N2110KShares$36,3000.12% of portfolio
-
Frontier Wealth Management LLC Kansas City, MO20.5KShares$6,7650.0% of portfolio
-
Corient Capital Partners, LLC Newport Beach, CA14.9KShares$4,9210.0% of portfolio
-
Huntington National Bank Columbus, OH5KShares$1,6500.0% of portfolio
About Sorrento Therapeutics, Inc.
- Ticker SRNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 449,952,000
- Market Cap $148M
- Description
- Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...